Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G3139 and Paclitaxel in Recurrent Small Cell Lung Cancer
NCT00005032Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Apr 2000
- Primary completion
- Jan 2001
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in small cell lung cancer (SCLC), sponsored by University of Chicago. Started Apr 2000; status: completed.
02
Drugs
oblimersen
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00005032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005032.